There existed several limitations in our study: (1) we only recruited the patients who were diagnosed with primary CRC, the clinical value of SOX30 in patients with secondary CRC could be investigated in the future; (2) the present study was a retrospective study, which might exist a series of compound factors and bias; however, we tried to use multivariate Cox’s regression model analysis to eliminate partial interfering factors; (3) the role of SOX30 in the regulatory mechanism of CRC could be investigated and further to explore the therapeutic value of SOX30 in CRC. Here, SOX30 is linked to colorectal carcinoma.